Document is current
Any future updates will be listed below
-
Authors
Swolin-Eide, Diana https://orcid.org/0000-0001-9633-6673
Forsander, Gun https://orcid.org/0000-0002-0266-9651
Pundziute Lyckå, Auste https://orcid.org/0000-0001-9731-5559
Novak, Daniel https://orcid.org/0000-0002-7892-7880
Grillari, Johannes https://orcid.org/0000-0001-5474-6332
Diendorfer, Andreas B. https://orcid.org/0000-0003-0331-9685
Hackl, Matthias https://orcid.org/0000-0002-4136-7293
Magnusson, Per https://orcid.org/0000-0002-2123-7838
-
Funding
Funding for this research was provided by:
ALF-grants Gothenburg (ALFGBG-716831, 678871, 965009)
The Swedish Child Diabetes Foundation
Swedish Diabetes Foundation
ALF-grants Region Östergötland
Linköping University
- License Information
-
More Information
Article History
Received: 15 February 2023
Accepted: 11 July 2023
First Online: 19 July 2023
Competing interests
: Disclosure summary: A.B.D. and M.H. are employed by TAmiRNA GmbH. J.G. and M.H. are shareholders of TAmiRNA and hold IP in relation to the diagnostic use of circulating miRNAs. The other authors do not have any competing interests.
